Elacridar,98%

(The order shall be subject to the English name)

Product No.：E33100 CAS.：143664-11-3 Molecular formula：C₃₄H₃₃N₃O₅ MDL：MFCD00912604 Brand：Acmec

N-(4-(2-(6,7-二甲氧基-3,4-二氢异喹啉-2(1H)-基)乙基)苯基)-5-甲氧基-9-氧代-9,10-二氢吖啶-4-甲酰胺

Guess you like

Iron(III) 4-methylbenzenesulfonate hexahydrate, ≥98%（HPLC）

CAS No：312619-41-3

Titanium tetrafluoride, 98%

CAS No：7783-63-3

Ytterbium(III) chloride hexahydrate, 99.90%

CAS No：10035-01-5

Galanthamine hydrobromide from Lycoris sp., 98%

CAS No：1953-04-4

MQAE, 99%

CAS No：162558-52-3

28-Homobrassinolide, Extra pure，95%

CAS No：80483-89-2

ELISA Coating Buffer,1×, BR

CAS No：

Trifluridine/tipiracil hydrochloride mixture, 98%

CAS No：733030-01-8

Anti-RBCK1 Polyclonal Antibody, BR

CAS No：

Anti-FH Polyclonal Antibody, BR

CAS No：

Staphylococcus Aureus CMCC（B）26003, BR

CAS No：

D-Ribose 5-phosphate disodium dihydrate, 99%

CAS No：207671-46-3

1-(2-Amino-3-methoxyphenyl)ethanone, 95%

CAS No：42465-54-3

Recombinant Human CD157/BST1/ADP-ribosyl cyclase 2/Cyclic ADP-ribose hydrolase 2, BR

CAS No：

Rat Organ Tissue Lymphocyte Isolation Solution Kit, BR

CAS No：

Fmoc-Ala-Ala-OH, 98%

CAS No：87512-31-0

Phosal 50 PG, 98%

CAS No：774594-96-6

Tizanidine hydrochloride, 98%

CAS No：64461-82-1

1,2-DIAMINO-2-METHYLPROPANE, 97%

CAS No：811-93-8

3-Aminobenzophenone 97%, 97%

CAS No：2835-78-1

Introduction
Security information

Name：

Elacridar

CAS No.：

143664-11-3

Molecular formula：

C₃₄H₃₃N₃O₅

Molecular weight：

563.64

Density：

1.264±0.06 g/cm3(Predicted)

MeltingPoint：

216-218°C

BoilingPoint：

701.6±60.0°C(Predicted)

Solubility：

DMSO:41 mg/mL (72.74 mM);Ethanol:<1 mg/mL;Water:<1 mg/mL

WaterSolubility：

<1 mg/mL

Preservation conditions：

-20°C,Dark,Dry

InChIKey：

OSFCMRGOZNQUSW-UHFFFAOYSA-N

InChI：

InChI=1S/C34H33N3O5/c1-40-28-9-5-7-26-32(28)36-31-25(33(26)38)6-4-8-27(31)34(39)35-24-12-10-21(11-13-24)14-16-37-17-15-22-18-29(41-2)30(42-3)19-23(22)20-37/h4-13,18-19H,14-17,20H2,1-3H3,(H,35,39)(H,36,38)

Pubchem ID：

119373

Biological Activity:
Elacridar (GF120918; GW0918) is a P-glycoprotein inhibitor, and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules.
Target: P-glycoprotein
In vitro, GF120918A demonstrated high plasma protein binding across species, although a definitive protein binding evaluation was precluded by poor recovery, particularly in buffer and in mouse, rat, and dog plasma. GF120918A did not demonstrate potent inhibition of several human cytochrome P450 enzymes evaluated in vitro, with IC(50) values well above concentrations anticipated to be achieved in vivo. Together, these data confirm the utility of GF120918A as a tool P-glycoprotein inhibitor in preclinical species and offer additional guidance on preclinical dose regimens likely to produce P-glycoprotein-mediated effects.

Solvent & Solubility: 10 mM in DMSO

Grade of hazardous chemicals：

For detailed properties of compounds, click“143664-11-3”

technical information

History browsing record